<http://webisa.webdatacommons.org/147598812>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<baxter.com> .
<http://webisa.webdatacommons.org/147598812>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/prov/283686379>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/147598812> .
<http://webisa.webdatacommons.org/147598812>	<http://www.w3.org/ns/prov#value>	"The biopharmaceuticals business, with 2013 annual revenues of approximately $6 billion, consists of a diverse portfolio of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders, and plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions." .